University of Oxford

Pharminox Ltd, a private oncology R&D company backed by IP Group, is to carry out joint research into novel small molecule chemotherapeutics with Schering-Plough.

A spin-out from Oxford University is looking to attract the attention of equity investors and pharmaceutical companies by focusing on the discovery and development of small molecules to treat cancer